Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 10/20 | 0.39 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29100989 | 0.86 | MRGPRX4 (0.50) | BACE1MRGPRX4KMT2AKDM4EALDH1A1 | |
| SCHEMBL30630386 | 0.86 | MRGPRX4 (0.50) | BACE1MRGPRX4KMT2AKDM4EALDH1A1 | |
| SCHEMBL25201867 | 0.85 | BACE1 (0.41) | BACE1MRGPRX4SGMS2KAT6AMAPT | |
| SCHEMBL20436602 | 0.82 | BACE1 (0.38) | BACE1MRGPRX4KAT6A | |
| SCHEMBL15000653 | 0.80 | BACE1 (0.43) | BACE1TACR1 | |
| SCHEMBL3076782 | 0.79 | BACE1 (0.40) | BACE1KMT2AMAOB | |
| SCHEMBL15000893 | 0.78 | CYP4F2 (0.45) | BACE1 | |
| SCHEMBL31658767 | 0.78 | MAOB (0.40) | BACE1SGMS2MAOBMAPTHPGD | |
| SCHEMBL29995380 | 0.77 | BACE1 (0.39) | BACE1TACR1 | |
| SCHEMBL29101037 | 0.77 | BACE1 (0.39) | BACE1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144808-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11072597-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. | 2021-07-27 | — | — | US | disclosed |
| US-20210101880-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10399962-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144808-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | BACE1 4667/4885MRGPRX4 163/4885SGMS2 4498/4885 |
| US-11072597-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | BACE1 4667/4885MRGPRX4 163/4885SGMS2 4498/4885 |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | BACE1 4667/4885MRGPRX4 163/4885SGMS2 4498/4885 |
| US-10399962-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | BACE1 4667/4885MRGPRX4 163/4885SGMS2 4498/4885 |
| US-20210101880-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | BACE1 4667/4885MRGPRX4 163/4885SGMS2 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.